Recommendations for Dose Adjustments of Infliximab in Crohn's Disease Patients with Higher Clearance

被引：0
|
作者：
Andersson, Helena [1 ,2 ]
Eser, Akexander [3 ]
Huisinga, Wilhelm [4 ]
Reinisch, Walter [3 ]
Kloft, Charlotte [1 ]
机构：
[1] Free Univ Berlin, Inst Pharm, Dept Clin Pharm & Biochem, Berlin, Germany
[2] Grad Res Training Program PharMetrX, Berlin, Germany
[3] Med Univ Vienna, Dept Gastroenterol & Hepatol, Vienna, Austria
[4] Univ Potsdam, Inst Math, Potsdam, Germany
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-045
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [31] Need for infliximab dose intensification in Crohn's disease and ulcerative colitis
    Taxonera, Carlos
    Olivares, David
    Mendoza, Juan L.
    Diaz-Rubio, Manuel
    Rey, Enrique
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (27) : 9170 - 9177
  • [32] Need for infliximab dose intensification in Crohn's disease and ulcerative colitis
    Carlos Taxonera
    David Olivares
    Juan L Mendoza
    Manuel Díaz-Rubio
    Enrique Rey
    [J]. World Journal of Gastroenterology, 2014, 20 (27) : 9170 - 9177
  • [33] Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration
    Edlund, Helena
    Steenholdt, Casper
    Ainsworth, Mark A.
    Goebgen, Eva
    Brynskov, Jorn
    Thomsen, Ole O.
    Huisinga, Wilhelm
    Kloft, Charlotte
    [J]. AAPS JOURNAL, 2017, 19 (01): : 223 - 233
  • [34] Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn’s Disease Is Determined by Their Concentration
    Helena Edlund
    Casper Steenholdt
    Mark A. Ainsworth
    Eva Goebgen
    Jørn Brynskov
    Ole Ø. Thomsen
    Wilhelm Huisinga
    Charlotte Kloft
    [J]. The AAPS Journal, 2017, 19 : 223 - 233
  • [35] Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
    Hisamatsu, Tadakazu
    Kunisaki, Reiko
    Nakamura, Shiro
    Tsujikawa, Tomoyuki
    Hirai, Fumihito
    Nakase, Hiroshi
    Watanabe, Kenji
    Yokoyama, Kaoru
    Nagahori, Masakazu
    Kanai, Takanori
    Naganuma, Makoto
    Michimae, Hirofumi
    Andoh, Akira
    Yamada, Akihiro
    Yokoyama, Tadashi
    Kamata, Noriko
    Tanaka, Shinji
    Suzuki, Yasuo
    Hibi, Toshifumi
    Watanabe, Mamoru
    [J]. INTESTINAL RESEARCH, 2018, 16 (03) : 494 - +
  • [36] BACTERIAL CLEARANCE IS DELAYED IN PATIENTS WITH CROHN'S DISEASE
    Hayee, B.
    Rahman, F. Z.
    Smith, A. M.
    Marks, D. J. B.
    Sewell, G. W.
    Sweeting, T. J.
    Bloom, S. L.
    Segal, A. W.
    [J]. GUT, 2009, 58 : A14 - A15
  • [37] Transmural healing is associated with higher infliximab trough levels in Crohn's disease
    Albshesh, A.
    Unger, B.
    Ben Horin, S.
    Eliakim, R.
    Kopylov, U.
    Carter, D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S454 - S454
  • [38] Discussion on predictors of response to infliximab in patients with Crohn's disease
    Hommes, D
    [J]. GASTROENTEROLOGY, 2003, 124 (07) : 2002 - 2003
  • [39] Infliximab improves quality of life in patients with Crohn's disease
    Lichtenstein, GR
    Bala, M
    Han, CL
    DeWoody, K
    Schaible, T
    [J]. INFLAMMATORY BOWEL DISEASES, 2002, 8 (04) : 237 - 243
  • [40] Resource use in patients with Crohn's disease treated with infliximab
    Saro, C.
    de la Coba, C.
    Casado, M. A.
    Morales, J. M.
    Otero, B.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (10) : 1313 - 1323
12345